reports
GSK: 1 director
A director at GSK sold 6,000 shares at 1,702p and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close p...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarte...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on Tuesday, May 14, 2024 after the market close. The Company will host a conference call to discuss the results the following morning, May 15th, at 8:30 a.m. ET. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of...
Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected P...
Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags TARRYTOWN, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- 1949 was a big year for barf, welcoming the invention of the barf bag and . Seventy-five years later, Dramamine, a Prestige Consumer Healthcare brand, thrives as the number one brand for motion sickness relief, but as Dr...
Merck Kgaa: 2 directors
Two Directors at Merck Kgaa bought 7,768 shares at 159.245EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
PRGO PERRIGO CO. PLC
GOGO GOGO INC.
D DOMINION ENERGY INC
CTRN CITI TRENDS INC.
CLFD CLEARFIELD INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
HWBK HAWTHORN BANCSHARES
FMC FMC CORPORATION
RIGN TRANSOCEAN LTD.
SPWR SUNPOWER CORPORATION
AFT APOLLO SENIOR FLOATING RATE FUND INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
HCC WARRIOR MET COAL INC.
RBB RBB BANCORP
AXR AMREP
FSK FS KKR CAPITAL CORP
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
BSBK BOGOTA FINANCIAL CORP.
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
THRY THRYV HOLDINGS
ABCL ABCELLERA BIOLOGICS
LSEA LANDSEA HOMES CORP (A)
LUMN LUMEN TECHNOLOGIES INC.
SLRC SOLAR CAPITAL LTD.
ONDS ONDAS HOLDINGS
PFX PHENIXFIN CORP
WES WESTERN MIDSTREAM PARTNERS LP
ABSI ABSCI CORP
VPV INVESCO PA VALUE MUNI INC TST
GATO SUNSHINE SILVER MINING AND REFINING CORP
LSXMA LIBERTY SIRIUSXM GROUP
LSXMK BURKE HERBERT FINANCIAL SERVICES CORP
BHRB ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
MDRX INC.
Perrigo Co: 1 director
A director at Perrigo Co bought 4,035 shares at 26.946USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Jonathan Moreland
- Salome Charamalet
- Stefano Toffano
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/07/2024
We are initiating coverage of Lonza with a target price of CHF 535 and an Outperform rating. As one of the world's leading contract development and manufacturing organisations (CDMO), Lonza is predestined to benefit from the sustainable drivers of this industry. The group's global presence and strong market positions in the growth areas of biologics and cell and gene therapy (CGT) will fuel double-digit sales growth and >30% EBITDA margins in the medium term. Despite significant growt...
LHA DEUTSCHE LUFTHANSA AG
JMT JERONIMO MARTINS SGPS S.A.
G1A GEA GROUP AG
RCO REMY COINTREAU SA
SCR SCOR SE
TEP TELEPERFORMANCE SE
RF EURAZEO SA
MRK MERCK KGAA
BAYN BAYER AG
TIT TELECOM ITALIA S.P.A.
BNR BRENNTAG SE
PIRC PIRELLI & C. S.P.A.
NEXI NEXI S.P.A.
AZE AZELIS GROUP NV
- Salome Charamalet
- Stefano Toffano
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 07/03/2024
We are initiating coverage of Lonza with a target price of CHF 535 and an Outperform rating. As one of the world's leading contract development and manufacturing organisations (CDMO), Lonza is predestined to benefit from the sustainable drivers of this industry. The group's global presence and strong market positions in the growth areas of biologics and cell and gene therapy (CGT) will fuel double-digit sales growth and >30% EBITDA margins in the medium term. Despite significant growt...
LHA DEUTSCHE LUFTHANSA AG
JMT JERONIMO MARTINS SGPS S.A.
G1A GEA GROUP AG
RCO REMY COINTREAU SA
SCR SCOR SE
TEP TELEPERFORMANCE SE
RF EURAZEO SA
MRK MERCK KGAA
BAYN BAYER AG
TIT TELECOM ITALIA S.P.A.
BNR BRENNTAG SE
PIRC PIRELLI & C. S.P.A.
NEXI NEXI S.P.A.
AZE AZELIS GROUP NV
- Oliver Metzger
Merck KGaA : FY review -Outlook better on healthcare, but more cautiou...
>Q4 review – Slight beat in Q4 - Q4 2023 revenues of € 5,225m (-7.7% y-o-y) were 0%/+2% vs ODDO BHF/consensus. The organic decline was -2.9%, (ODDO BHF -3.8%). EBITDA pre of € 1,293m (-19.8% y-o-y, margin 24.7%) was 5%/1% better than ODDO BH/consensus. Core EPS was € 1.85 some 0%/3% ahead of expectations on a lower tax rate. For 2024, the company expects slight to modest organic growth with a forex headwind of 0% to -3% (ODDO BHF 4.9% organic growth, consensus 1.8% in...
Prestige Consumer Healthcare Inc: 2 directors
Two Directors at Prestige Consumer Healthcare Inc sold after exercising options/sold 56,038 shares at between 67.899USD and 68.353USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
- Dominic Rose
- Naresh Chouhan
GSK - It’s Not Sexy But It Is a BUY (TP £19 [£14.50], 14 pgs)
Following new analysis on current growth drivers & upcoming pipeline readouts, we upgrade our 2028 revenues by £2.5bn & believe GSK can deliver 11% CAGR EPS growth 2024-27 leaving us 7% above consensus 2027 EPS. Whilst we believe 2029-31 is an unfillable hole & justifies a low multiple on Pharma, this is more than in the price and near-term momentum will likely drive the shares higher. The Zantac overhang clearing, some pipeline catalysts & the potential for fresh management coupled with near-te...
Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Re...
Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter EndRaising Full-Year Fiscal 2024 Earnings Outlook to Approximately $4.33 TARRYTOWN, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2023. “We are pleased with our continued strong results that exceeded our revenue and earnings expe...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1%...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredi...
- Anthony Dick
- Michael Foundoukidis
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/02/2024
Sodexo boasts a defensive profile and significant potential for operational improvement, with progress increasingly visible since Sophie Bellon’s arrival as CEO. These factors are set to endure, narrowing the gap with Compass, and its transformation into a catering pure player following Pluxee’s spin-off in early 2024 should facilitate the group’s rerating. Outperform rating reiterated and a target price € 98 following Pluxee’s spin-off (combined Sodexo + Pluxee target price of € 12...
- Anthony Dick
- Michael Foundoukidis
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 02/02/2024
Sodexo bénéficie d’un profil défensif et d’un fort potentiel d’amélioration opérationnelle, avec des progrès de plus en plus visibles depuis l’arrivée de Sophie Bellon comme CEO. Ceux-ci devraient se poursuivre, réduisant l’écart avec Compass, et sa transformation en un pure player, à la suite du spin-off de Pluxee début 2024, devrait faciliter son rerating boursier. Surperformance réitérée et OC à 98 € à la suite du spin-off de Pluxee (OC combinés Sodexo + Pluxee à 129 € vs OC de 118...
- Oliver Metzger
Merck KGaA : Factor in Life Sciences with slower finish, Electronics w...
>Q4 preview – Ongoing weak momentum - Q4 revenues of € 5,131m (-9.3% y-o-y) should be impacted by an organic decline of -3.8% and forex headwind of 550bp. Within the divisions, we see the strongest decline coming from Life Sciences with an organic decline of 12.1% on the back of ongoing destocking. We forecast Electronics to decline by 4.3% organically on the back of a weak semiconductor market. On the other hand, Healthcare is expected to grow with a strong 7.0% in t...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third quarter earnings release on Thursday, February 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the conference call v...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americai...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene TARRYTOWN, N.Y., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level. While benzene is not an ingredient in any Americaine® 20% Benzocaine Topical Anesthetic Spray products, a recent review by our manufacturer and their third-party lab found that a sample from one lot of the ...
- Dominic Rose
- Naresh Chouhan
EU Pharma - 2024 Year Ahead (28 pgs)
For EU Pharma, 2024 is likely to be characterised by EPS revisions, a handful of new launches & sluggish EPS growth for a number of names. The relative lack of pipeline catalysts makes forecasting sales and EPS much more important than for 2023. We identify 4 key issues to watch for: 1) Medicaid AMP cap removal, 2) Higher tax costs, 3) Higher debt costs & 4) a handful of very specific company issues that could make a material difference to performance (Novo: Wegovy supply, GSK: litigation, SAN: ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.